Deva Holding A.S. (DEVA.IS)
- Previous Close
57.95 - Open
57.95 - Bid 56.50 x --
- Ask 56.65 x --
- Day's Range
56.55 - 58.15 - 52 Week Range
53.55 - 106.00 - Volume
460,331 - Avg. Volume
665,704 - Market Cap (intraday)
11.311B - Beta (5Y Monthly) -0.38
- PE Ratio (TTM)
18.48 - EPS (TTM)
3.06 - Earnings Date May 9, 2025
- Forward Dividend & Yield 0.25 (0.43%)
- Ex-Dividend Date Jun 25, 2024
- 1y Target Est
--
Deva Holding A.S. manufactures, markets, and sells pharmaceutical products in Turkey. The company offers antineoplastic and immunomodulating agents; dermatological products; sysyemic hormanal preparations; anti-infective and antiparasitic products for systemic use; food supplements; and electrolyte solutions. It also provides products in the areas of urogenital system and sex hormones, blood and blood forming organs, cardiovascular system, musculoskeletal system, nervous system, alimentary tract and metabolism, respiratory system, urinary systems, connective tissue, and sensory organs. In addition, the company offers various products in sterile and non-sterile forms, including liquids, semi-solids, solids, cephalosporins, penicillin, hormone and inhalation products, solid and liquid oncology, animal health products, active pharmaceutical ingredients, ampoules, liquid and lyophilized vials, eye drops, medical ampoules for sterile injectable products, and cologne. It also exports its products to approximately 60 countries. The company was incorporated in 1958 and is based in Istanbul, Turkey. Deva Holding A.S. is a subsidiary of Eastpharma S.à R.L.
www.deva.com.tr3,101
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DEVA.IS
View MorePerformance Overview: DEVA.IS
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is BIST 100 (XU100.IS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DEVA.IS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DEVA.IS
View MoreValuation Measures
Market Cap
11.59B
Enterprise Value
14.71B
Trailing P/E
18.94
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.79
Price/Book (mrq)
0.51
Enterprise Value/Revenue
1.00
Enterprise Value/EBITDA
3.49
Financial Highlights
Profitability and Income Statement
Profit Margin
4.17%
Return on Assets (ttm)
2.38%
Return on Equity (ttm)
3.12%
Revenue (ttm)
14.7B
Net Income Avi to Common (ttm)
612.12M
Diluted EPS (ttm)
3.06
Balance Sheet and Cash Flow
Total Cash (mrq)
2.94B
Total Debt/Equity (mrq)
26.62%
Levered Free Cash Flow (ttm)
-2.78B